Stockholm, Sweden

Håkan Mellstedt


 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2015-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Håkan Mellstedt: Innovator in Tyrosine Kinase Inhibition

Introduction

Håkan Mellstedt, based in Stockholm, Sweden, is a notable inventor in the field of biochemistry and pharmacology. With two patents to his name, Mellstedt has made significant contributions to the development of inhibitors for mammalian tyrosine kinase ROR1 activity. His work is paving the way for new treatments for disorders associated with tyrosine kinase enzyme activity.

Latest Patents

Håkan Mellstedt's latest patents focus on 2-phenylimidazo[4,5-b]pyridin-7-amine derivatives. These compounds are recognized for their potential as inhibitors of mammalian tyrosine kinase ROR1 activity. Specifically, the patents encompass the formulation of these compounds, either in their native forms or as pharmaceutically acceptable salts. The compounds may be effectively utilized in treating disorders linked to ROR1 tyrosine kinase activity, showcasing their significant medical potential.

Career Highlights

Currently working with Kancera AB, a company dedicated to developing treatments targeting cancer and other serious diseases, Mellstedt has been at the forefront of innovative research in medicinal chemistry. His work with tyrosine kinase inhibitors marks a noteworthy advancement in therapeutic strategies that address complex health issues.

Collaborations

Throughout his career, Håkan Mellstedt has collaborated with talented colleagues such as Styrbjörn Byström and Jan Vågberg. These partnerships exemplify the collaborative spirit of scientific research, bringing together diverse expertise to drive innovation in the pharmaceutical landscape.

Conclusion

Håkan Mellstedt stands out as a prominent inventor in the realm of biochemistry, with significant contributions highlighted by his patents. His dedication to developing effective therapies for disorders related to tyrosine kinase activity reflects his commitment to advancing healthcare solutions. As he continues his work at Kancera AB, Mellstedt is poised to make further impactful strides in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…